DAX-0,03 % EUR/USD+0,40 % Gold+0,64 % Öl (Brent)0,00 %

Tenbagger - Bionovo !?! - Die letzten 30 Beiträge

Nasdaq OTC
-25,00 %
-0,0001 USD

Neuigkeiten zur Bionovo Aktie

Beitrag schreiben

Begriffe und/oder Benutzer


Antwort auf Beitrag Nr.: 43.985.911 von hamburgundelbe am 05.01.13 18:09:07ist tot :mad:
Antwort auf Beitrag Nr.: 43.983.064 von michael_lebt am 04.01.13 17:52:30.... scheint mir nach etwas genauerer Durchleuchtung
auch nicht unbedingt lukrativ ....

finger weg! nur bauchgefühl

Antwort auf Beitrag Nr.: 43.054.355 von Goldbaba am 18.04.12 12:35:31übersehen?

Bionovo +94,3%

an der Heimatbörse

+0.0035 (13.46%)

Apr 17 - Close
PINK data delayed by 15 mins - Disclaimer
Currency in USD

bei 204 000 Stückzahl.

Bionovo's Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™

2012-03-28 11:59 ET - News Release

EMERYVILLE, Calif., March 28, 2012 /PRNewswire/ -- Bionovo, Inc. (OTCQB: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today that the Company's independent Data Safety Monitoring Board (DSMB) recommended that the Phase 3 trial of Menerba (MF101) could continue as designed after an initial review of its clinical safety and tolerability data. Menerba is Bionovo's oral botanical drug candidate designed for the safe and effective treatment of vasomotor symptoms (hot flashes) associated with menopause.

The DSMB evaluated unblinded safety and dose tolerability data after 66 participants were randomized and on study medication for at least 30 days. After an independent review of the data, the DSMB issued their positive recommendation to continue the trial as originally designed and no concerning safety signals were identified.

"I am very encouraged by the positive recommendation from our independent DSMB. This assurance that Menerba™ continues to be a safe, well-tolerated, non-estrogen alternative therapy for the treatment of menopausal hot flashes is consistent with the promising results of our early clinical trial data and extensive pre-clinical toxicity studies. We are very eager to continue to develop a safe and effective treatment for post-menopausal hot flashes, a drug that can be the leading seller in the well established multibillion dollar market," said Mary Tagliaferri, M.D., Bionovo's President and Chief Medical Officer.

The MF101-004 Phase 3 pivotal study dosed its first patient on November 16, 2011. To date, a total of 280 postmenopausal women have been randomized to the trial. Recruitment to the Phase 3 trial was voluntarily halted on March 9, 2012 as Bionovo does not have adequate funding to further advance the registration trial. Bionovo will need to secure additional financing to complete either a smaller Phase 2B trial with the current cohort of 280 randomized participants or to complete the planned Phase 3 study.

The purpose of the study is to evaluate the safety and efficacy of two doses of Menerba™ (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes. (Logo: http://photos.prnewswire.com/prnh/20111110/SF04662LOGO)

Participants are randomized to Menerba™ 5g/day, Menerba™ 10g/day or placebo and treated for 12 weeks. Efficacy will be measured by the reduction of moderate to severe hot flashes from baseline to 12 weeks of treatment Dr. Wulf Utian, Executive Director Emeritus and Honorary Founding President of the North America Menopause Society and Professor Emeritus at Case Western Reserve University is serving as the Principal Investigator for this study.

About Menerba
Menerba is an oral drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause, which is manufactured from botanical sources. Menerba™ is an estrogen receptor beta (ER-b) selective drug, developed as an alternative to the products currently on the market which have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with activation of estrogen receptor alpha (ER-a) and that activation of estrogen receptor beta (ER-b) blocks the growth promoting effects on breast cancer cells. The active ingredients in Menerba™ are derived from botanicals with centuries of recorded safe, effective use in traditional Chinese medicine (TCM). Bionovo recognizes the opportunity to commercialize a product that would be as effective as hormone therapy, without the health risks. Menerba™ has completed a Phase 2 trial with positive results for efficacy and has been evaluated by an independent Data and Safety Monitoring Board and passed through a standard two-round examination for safety. Menerba™ also has been shown in animal studies to prevent the proliferation of breast cancer and to have a beneficial effect on osteoporosis, though this has not yet been studied in humans.

Bionovo, Inc.
Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The Company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California. For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise

SOURCE Bionovo, Inc.


Article Date: 2012-03-22 11:22:08 AM
Five three-phase attention as a promising new drug candidates
Menopause and High Cholesterol drug side effects, including reduced

Reduce the side effects of conventional treatment of familial hypercholesterolemia and treatment of menopausal symptoms, such as three-phase drug candidates has been noted as a prospect.

In addition, Thomson Reuters in the world during the last quarter phase III trial of new drug candidates entered the Pseudomonas aeruginosa infections, allergies, gout cure was chosen primarily expected 5.

First, bio-Novo (Bionovo) treatment of menopausal hot flashes and night sweats Jane meneoba '(Menerba) an oral plant-derived estrogen receptor beta agonist in the risk of breast and cervical cancer as an alternative to hormone replacement therapy is expected.

That activation of estrogen receptor alpha to increase the risk of cancer of the breast tissue, but the activation of receptor beta to inhibit the growth is affected. In previous clinical studies hormone therapy and the effect was similar but safety.
Seit Hundert Jahren wird nach einem Medikament gegen Krebs gesucht,
bisher leider erfolglos.

Das sollte doch eigentlich zum Denken anregen?

Können seelische Wunden und Traumas mit physischen Anwendungen beseitigt werden?

Es heißt, hinter jedem Brustkrebs steht eine stressreiche Beziehung.
Antwort auf Beitrag Nr.: 42.937.690 von kirroyal am 21.03.12 19:53:52kommt auf die news an ist sie gut bis sehr gut dann 0,50 $ und mehr ist sie aber schlecht oder sehr schlecht dann 0,0000 :D

aber ohne news geht nichts also abwarten und tee trinken - entweder reich, steinreich oder hartz4

aber 1$ könnten schon mal gezockt werden ..........

Antwort auf Beitrag Nr.: 42.937.626 von Trading_Alert am 21.03.12 19:42:51Würde mich sehr darüber freuen...nur im Moner sieht es eben so aus

Ach ja, fällt mir noch ein...waren an der Nasdaq gelistet und jetzt PINKIS
2012-03-12 11:59 BNVI News Release Bionovo Enters Into Agreement for Offering of Common Stock and Warrants
2012-03-09 20:00 BNVI News Release Bionovo Restructures Work Force Management Compensation Restructured
2012-03-08 08:00 BNVI News Release Bionovo President & CMO Receives Women of the Year Award
Antwort auf Beitrag Nr.: 42.937.469 von Trading_Alert am 21.03.12 19:18:37Hi,

kenne diesen Wert ...R/S mitgemacht und 99 % Verlust im Depot !

Kann nur sagen , sehr volatil das Ding !

Ganz ehrlich , habe sie als Depotleiche abgestempelt ...

Die letzten NEWS vom 29.2.12

Wer kennt diesen BioTECH Wert - Bionovo Inc. ?
Bei einem Börsenwert von sage und schreibe 2,9 Mio € könnte diese Aktie wahres Tenbagger Potential versprechen.
Hier lauern nach dem Abschluß einer Finanzierung schnell 150 - 200 %

Bionovo, Inc.(Bionovo) ist ein US-amerikanisches Biopharma-Unternehmen im Bereich Entdeckung und Entwicklung von sicheren und wirksamen Arzneimitteln zur Behandlung von BrustKrebs u. a. Krebsarten.

Analysten aus den USA sahen 2011 ein Kursziel zwischen 7,50 - 5 $ aktuell 0,04 €.:eek::eek: CRV ist sensationell ...... entweder 5000 % oder TV !!!!

LifeTech Capital Maintains Bionovo Strong Speculative Buy

LifeTech Capital maintained its Bionovo (NASDAQ: BNVI [2]) Strong Speculative Buy rating and lowered its Bionovo price target from $7.50 to $5 in a research report published today.

In the report, LifeTech Capital states, "Menerba could become the first botanical blockbuster drug which we believe represents an intriguing opportunity for patient investors."

Shares of Bionovo were trading at $0.69 at the time of posting, down 12.41% from Tuesday's market close.


Beitrag zu dieser Diskussion schreiben